Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Novel immunotherapies for multiple myeloma & other exciting developments

Wee Joo Chng • 29 Sep 2023
IMS 2023
Multiple Myeloma Antibodies CAR-T

Wee Joo Chng, MB ChB, MRCP, MRCPath, PhD, National University of Singapore, Singapore, provides an overview of the latest updates in immunotherapies for multiple myeloma. The development of bispecific antibodies and T-cell engagers targeting BCMA and GPRC5D will potentially give patients more treatment options. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Wee Joo Chng

1:57
Treatment options for patients with multiple myeloma refractory to lenalidomide
Wee Joo Chng • 29 Sep 2023
2:08
Highlights of IMS 2023: the origins of myeloma and the role of the microenvironment
Wee Joo Chng • 29 Sep 2023
1:32
Metabolic reprogramming confers resistance to lenalidomide in multiple myeloma
Wee Joo Chng • 29 Sep 2023
1:58
The role of STAT3 signaling in multiple myeloma
Wee Joo Chng • 26 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals